Lamberto Andreotti - Bristol Myers CEO, Director
CEO
Mr. Lamberto Andreotti is no longer a NonExecutive Chairman of the Board of BristolMyers Squibb Company effective as of May 2nd, 2017. He has served as Executive Chairman of the Board of the Company from May 5, 2015 to August 3, 2015. He is no longer Chief Executive Officer of the Company effective May 5, 2015. He was Chief Executive Officer, Director of BristolMyers Squibb Company. Mr. Andreotti was Chief Executive Officer since May 2010. He was our President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS since 2015.
| Age | 64 |
| Tenure | 9 years |
| Phone | 212-546-4000 |
| Web | http://www.bms.com |
Similar Executives
| Showing other executives | CEO Age | ||
| Yoshihiko Hatanaka | Astellas Pharma | 61 | |
| Severin Schwan | Roche Holding AG | 56 | |
| Pascal Soriot | AstraZeneca PLC | 58 | |
| Yoshihiko Hatanaka | Astellas Pharma | 61 | |
| Paul Hudson | Novartis AG | 51 | |
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Chris Ilsley | Novartis AG | N/A | |
| Bruno Strigini | Novartis AG ADR | N/A | |
| Joji Nakayama | Daiichi Sankyo | 67 | |
| Francesco Balestrieri | Novartis AG | N/A | |
| Richard Saynor | Novartis AG ADR | 57 | |
| Michael Heuer | Roche Holding AG | 64 | |
| Michael Heuer | Roche Holding Ltd | 64 | |
| Patrick Thomas | Bayer Aktiengesellschaft | 57 | |
| Masao Yoshida | Astellas Pharma | N/A | |
| Chris Ilsley | Novartis AG ADR | N/A | |
| Joseph Jimenez | Novartis AG | 58 | |
| Liam Condon | Bayer Aktiengesellschaft | 50 | |
| Pascal Soriot | AstraZeneca PLC ADR | 60 | |
| Tatsuo Higuchi | Otsuka Holdings Co | 73 | |
| Susanne Schaffert | Novartis AG | 51 | |
Bristol Myers Squibb Leadership Team
Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ann Powell, Chief Human Resource Officer, Senior Vice President | ||
| Togo West, Independent Director | ||
| Karen Vousden, Director | ||
| Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer | ||
| Alan Lacy, Independent Director | ||
| Robert Bertolini, Independent Director | ||
| Jose Baselga, Independent Director | ||
| Charles Bancroft, CFO, Executive Vice President | ||
| Gerald Storch, Independent Director | ||
| Louis Schmukler, President - Global Manufacturing and Supply | ||
| Michael Grobstein, Independent Director | ||
| Christopher Boerner, Executive Vice President and Chief Commercial Officer | ||
| John Elicker, Senior Vice President - Public Affairs and Investor Relations | ||
| Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer | ||
| Karen Santiago, Senior Vice President Controller | ||
| Giovanni Caforio, COO, Director | ||
| Vicki Sato, Independent Director | ||
| Emmanuel Blin, Senior Vice President Chief Strategy Officer | ||
| Joseph Caldarella, Senior Vice President Corporate Controller | ||
| Laurie Glimcher, Independent Director | ||
| Murdo Gordon, Executive Vice President Chief Commercial Officer | ||
| Lamberto Andreotti, CEO, Director | ||
| Thomas Lynch, Independent Director | ||
| Dinesh Paliwal, Independent Director | ||
| Lewis Campbell, Independent Director | ||
| Theodore Samuels, Independent Director | ||
| Samuel Moed, Senior Vice President - Strategic Planning and Analysis | ||
| Matthew Emmens, Independent Director | ||
| Ann Judge, Senior Vice President - Global Human Resources | ||
| Sandra Leung, General Counsel, Corporate Secretary | ||
| Paul Autenried, Senior Vice President - Enterprise Services, CIO | ||
| Francis Cuss, Executive Vice President Chief Scientific Officer | ||
| Paul Biondi, Senior Vice President Head - Business Development | ||
| Peter Arduini, Independent Director |
Bristol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myers in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myers' short interest history, or implied volatility extrapolated from Bristol Myers options trading.
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Eaton PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eaton PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eaton PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eaton PLC to buy it.
The correlation of Eaton PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eaton PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eaton PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eaton PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Bristol Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |